WEST LAFAYETTE, Ind. \u2014 Intellicule, a software company whose solutions determine the 3D structures of biomolecules imaged with cryogenic-electron microscopy (cryo-EM), has received a $217,941 Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health.<\/p>\n\n\n\n
Daisuke Kihara, who leads Intellicule, said the grant will be used to develop software technology that could impact precision medicine.<\/p>\n\n\n\n
\u201cIt will have the potential to accelerate the development of novel drugs by offering precise structural information that can guide the design of molecules with improved efficacy,\u201d he said.<\/p>\n\n\n\n
Kihara<\/a> is a professor of biological sciences<\/a> and computer science<\/a> in Purdue University\u2019s College of Science<\/a>. He also is a member of the Purdue Institute for Cancer Research<\/a> and Purdue Institute for Drug Discovery<\/a>. Charles Christoffer, senior computational scientist in the Rosen Center for Advanced Computing<\/a>, and Genki Terashi, assistant research scientist in the Department of Biological Sciences, are the other founders.<\/p>\n\n\n\n Kihara said cryo-EM is a widely used experimental technique for determining three-dimensional structures of biological macromolecules like proteins, nucleic acids and ligands including drug molecules.<\/p>\n\n\n\n \u201cIts impact is not confined to academic research alone,\u201d he said. \u201cBiotech and pharmaceutical companies have increasingly adopted cryo-EM for its ability to provide detailed structural insights into biological targets.\u201d<\/p>\n\n\n\n Kihara said there is a challenge in using cryo-EM for drug discovery: achieving a high resolution better than 3 angstroms (\u00c5) is not always guaranteed.<\/p>\n\n\n\n \u201cWhen the resolution is worse than 3 \u00c5, ligands may still be visible, but the process of modeling becomes considerably more time-consuming and error-prone,\u201d he said. \u201cThis underscores the need for advanced software tools that can streamline the modeling process, reduce errors and make cryo-EM more accessible to nonspecialists in drug discovery efforts.\u201d<\/p>\n\n\n\n Kihara said the Phase I SBIR project aims to expand and advance structural modeling and analysis for drug discovery using cryo-EM by utilizing state-of-the-art deep-learning techniques.<\/p>\n\n\n\n \u201cThe intellectual merit of this project lies in its methodology, which overcomes the current limitations in biomolecular modeling for cryo-EM data,\u201d he said.<\/p>\n\n\n\n Kihara said deep learning is at the core of Intellecule\u2019s modeling software.<\/p>\n\n\n\n \u201cDeep learning is a powerful type of artificial intelligence particularly effective in image processing,\u201d he said. \u201cIn this software, it enables the detection of atoms in low-resolution cryo-EM images, something that would otherwise be extremely difficult to achieve.\u201d<\/p>\n\n\n\n Intellicule was formerly known as Molecular Intelligence; the company was launched in summer 2024. The Purdue Innovates Office of Technology Commercialization<\/a> issued the company an exclusive license to sell the software in January 2025.<\/p>\n\n\n\n This work is part of Purdue\u2019s One Health initiative<\/strong><\/a>, which brings together research on human, animal and plant health.<\/p>\n\n\n\n The Purdue Innovates Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university\u2019s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2024, the office reported 145 deals finalized with 224 technologies signed, 466 invention disclosures received, and 290 U.S. and international patents received. The office is managed by the Purdue Research Foundation, a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org<\/a> for more information.<\/p>\n\n\n\n Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in the United States, Purdue discovers, disseminates and deploys knowledge with a quality and at a scale second to none. More than 106,000 students study at Purdue across multiple campuses, locations and modalities, including more than 57,000 at our main campus in West Lafayette and Indianapolis. Committed to affordability and accessibility, Purdue\u2019s main campus has frozen tuition 14 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap \u2014 including its integrated, comprehensive Indianapolis urban expansion; the Mitch Daniels School of Business; Purdue Computes; and the One Health initiative \u2014 at https:\/\/www.purdue.edu\/president\/strategic-initiatives<\/a>.<\/p>\n\n\nDrawbacks in using cryo-EM<\/h2>\n\n\n\n
Focus of the NIH-grant-supported project<\/h2>\n\n\n\n
About Purdue Innovates Office of Technology Commercialization<\/h2>\n\n\n\n
About Purdue University<\/h2>\n\n\n\n